Table 3.
Guideline Concordance: CEA Testing*
| Characteristic | Meets or Exceeds |
Does Not Meet |
Univariate Odds Ratio | 95% CI | Multivariate Odds Ratio | 95% CI | ||
|---|---|---|---|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | |||||
| Age, years | ||||||||
| < 70 | 38 | 30.6 | 86 | 69.4 | 1 | Ref | 1 | Ref |
| ≥ 70 | 17 | 13.5 | 109 | 86.5 | 0.35 | 0.19 to 0.67 | 0.37 | 0.18 to 0.78 |
| Sex | ||||||||
| Male | 31 | 23.5 | 101 | 76.5 | 1 | Ref | ||
| Female | 24 | 20.3 | 94 | 79.7 | 0.83 | 0.46 to 1.52 | ||
| Residential location | ||||||||
| Rest of Manitoba | 31 | 32 | 66 | 68 | 1 | Ref | 1 | Ref |
| Winnipeg | 24 | 15.7 | 129 | 84.3 | 0.4 | 0.22 to 0.73 | 0.26 | 0.12 to 0.57 |
| Income† | ||||||||
| Low | 8 | 14 | 49 | 86 | 1 | Ref | ||
| High | 47 | 24.4 | 146 | 75.6 | 1.97 | 0.87 to 4.46 | ||
| Cancer site | ||||||||
| Rectum | 14 | 16.9 | 69 | 83.1 | 1 | Ref | 1 | Ref |
| Colon | 41 | 24.6 | 126 | 75.4 | 1.6 | 0.82 to 3.15 | 2.16 | 0.99 to 4.72 |
| Collaborative stage | ||||||||
| III | 37 | 31.1 | 82 | 68.9 | 1 | Ref | 1 | Ref |
| II | 18 | 13.7 | 113 | 86.3 | 0.35 | 0.19 to 0.66 | 0.38 | 0.18 to 0.80 |
| Comorbidity score‡ | ||||||||
| Low | 27 | 22.9 | 91 | 77.1 | 1 | Ref | ||
| High | 28 | 21.2 | 104 | 78.8 | 0.91 | 0.50 to 1.65 | ||
| Chemotherapy treatment | ||||||||
| No | 12 | 11.4 | 93 | 88.6 | 1 | Ref | 1 | Ref |
| Yes | 43 | 29.7 | 102 | 70.3 | 3.27 | 1.62 to 6.57 | 1.69 | 0.73 to 3.91 |
| Radiation treatment | ||||||||
| No | 44 | 22.3 | 153 | 77.7 | 1 | Ref | ||
| Yes | 11 | 20.8 | 42 | 79.2 | 0.91 | 0.43 to 1.92 | ||
| Oncologist contact§ | ||||||||
| No | 24 | 16.2 | 124 | 83.8 | 1 | Ref | 1 | Ref |
| Yes | 31 | 30.4 | 71 | 69.6 | 2.26 | 1.23 to 4.14 | 3.18 | 1.45 to 6.99 |
| Surgeon contact§ | ||||||||
| No | 34 | 20.9 | 129 | 79.1 | 1 | Ref | ||
| Yes | 21 | 24.1 | 66 | 75.9 | 1.21 | 0.65 to 2.24 | ||
| Internist contact§ | ||||||||
| No | 53 | 23.6 | 172 | 76.4 | 1 | Ref | ||
| Yes | — | 8.0 | 23 | 92.0 | 0.28 | 0.06 to 1.24 | ||
| FP/GP contact‖ | ||||||||
| Low | 28 | 16.6 | 141 | 83.4 | 1 | Ref | 1 | Ref |
| High | 27 | 33.3 | 54 | 66.7 | 2.52 | 1.36 to 4.66 | 2.71 | 1.32 to 5.58 |
NOTE. Bold type indicates statistically significant odds ratio and 95% CI. Dash indicates cell has been suppressed because its size is less than 5.
Abbreviations: CEA, carcinoembryonic antigen; FP, family practitioner; GP, general practitioner; Ref, reference.
The guideline is three tests or more performed in each and every 1-year interval starting with the 7th month after diagnosis.
Measured by income quintile [from 1 (lowest) to 5 (highest)]. Defined as low if income quintile = 1; otherwise high.
Measured by the number of the Major Adjusted Diagnostic Groups counts (range 0-6). Defined as low if count = 0 or 1; otherwise high.
At least one visit with a physician of this specialty in each and every year during the study period.
High FP contact signifies an annual number of visits to FPs that is above the median for the cohort in each and every year during the study period; otherwise low.